Glenmark Pharmaceuticals Limited

“Glenmark's India branded generics core is a real but modest compounder — mid-tier physician relationships in dermatology and respiratory provide a durable but not wide-moat position growing at 9-10% annually. The North America generics business is a structural drag. Management's Ichnos demerger — transferring the pipeline optionality to a promoter-favoured entity while leaving debt on the listed balance sheet — is an unremediated governance red flag that should permanently discount the stock. At 29x forward earnings near a 52-week high, with ROIC at 10-12%, net debt at 1.3-1.5x EBITDA, and FCF conversion still inconsistent, the market is pricing a clean recovery that is not yet proven. Probability-weighted 5-year returns are ~5% CAGR; 10-year base case is 1.5-2x — inadequate compensation for a promoter-controlled structure that has already demonstrated willingness to dilute minority holders for its own benefit.”